Influence of Intravitreal Therapy on Choroidal Thickness in Patients with Diabetic Macular Edema

被引:2
|
作者
Mirete, Patricia [1 ,2 ,3 ]
Munoz-Morata, Carmen [3 ]
Albarran-Diego, Cesar [3 ]
Espana-Gregori, Enrique [1 ,3 ]
机构
[1] Hosp Univ & Politecn La Fe, Dept Ophthalmol, Valencia 46026, Spain
[2] Aiken Clin, Valencia 46004, Spain
[3] Univ Valencia, Dept Surg, Valencia 46010, Spain
关键词
anti-VEGF; diabetic macular edema; dexamethasone implant; intravitreal therapy; OCT; aflibercept; ranibizumab; choroid; OPTICAL COHERENCE TOMOGRAPHY; ANTI-VEGF; RETINOPATHY; BIOMARKERS; MANAGEMENT;
D O I
10.3390/jcm12010348
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This study aimed to analyze the variation in subfoveal choroidal thickness (SFCT) and its relationship with the variation in central macular thickness (CME) in response to intravitreal therapy with an antiangiogenic (anti-VEGF) drug or corticosteroid in type 2 diabetic patients with diabetic macular edema (DME). Material and methods: This retrospective study included 70 eyes of 35 patients: 26 eyes received 4-5 intravitreal injections of aflibercept, 26 eyes were treated with a single intravitreal implant injection of dexamethasone, and 18 eyes without DME did not receive intravitreal therapy. SPECTRALIS (R) optical coherence tomography (OCT) (Heidelberg Engineering, Heidelberg, Germany) was used to measure the SFCT and CME before and at the end of the follow-up period. Results: The mean reductions in CME were 18.8 +/- 14.7% (aflibercept) and 29.7 +/- 16.9% (dexamethasone). The mean reductions in SFCT were 13.8 +/- 13.1% (aflibercept) and 19.5 +/- 9.6% (dexamethasone). The lowering effects of both parameters were significantly greater in the group treated with the dexamethasone implant (p = 0.022 and p = 0.046 for CMT and SFCT, respectively). Both therapies significantly decreased both CME and SFCT, independent of factors such as age, sex, previous intravitreal therapy, antidiabetic treatment, and the time of diabetes progression. There were no changes in the mean values of CME and SFCT in the untreated eyes. Conclusions: SFCT significantly decreased in response to intravitreal therapy with anti-VEGF or corticosteroids, irrespective of age, sex, previous intravitreal therapy, antidiabetic treatment, and the time of diabetes progression. There was a correlation between the changes in CME and SFCT after intravitreal therapy with aflibercept or dexamethasone implantation. SFCT was not a good predictor of the CME response but could be used to monitor the response to treatment. Local intravitreal therapy only affected the treated eye.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Choroidal thickness before and after intravitreal anti-VEGF therapy in patients with diabetic macular edema.
    Saini, Deepti
    Olson, Joanna
    Scott, Ingrid U.
    Bowie, Esther M.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [2] CHANGES IN SUBFOVEAL CHOROIDAL THICKNESS AFTER INTRAVITREAL DEXAMETHASONE IMPLANT THERAPY FOR DIABETIC MACULAR EDEMA
    Moon, Ka Young
    Choi, Shin Young
    Song, Ji Hun
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2021, 41 (06): : 1283 - 1292
  • [3] Choroidal Thickness Change in Patients With Diabetic Macular Edema
    Eliwa, Tamer F.
    Hegazy, Omnia S.
    Mahmoud, Safaa S.
    Almaamon, Tarek
    [J]. OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2017, 48 (12): : 970 - +
  • [4] Choroidal thickness is reduced in patients with diabetic macular edema
    Ferreras, Antonio
    Abadia, Beatriz
    Calvo, Pilar
    Sunen, Ines
    Bartol, Francisco
    Belen Pajarin, Ana
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [5] Foveal choroidal thickness in patients with diabetic retinopathy and diabetic macular edema
    Varughese, Rachel Sarah
    Rewbury, Rebecca
    Want, Andrew
    Chong, Victor
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [6] Effect of Intravitreal Triamcinolone Acetonide or Bevacizumab on Choroidal Thickness in Eyes With Diabetic Macular Edema
    Sonoda, Shozo
    Sakamoto, Taiji
    Yamashita, Takehiro
    Otsuka, Hiroki
    Shirasawa, Makoto
    Kakiuchi, Naoko
    Uchino, Eisuke
    Terasaki, Hiroto
    Kawano, Hiroki
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (06) : 3979 - 3985
  • [7] Subfoveal choroidal thickness in diabetic macular edema
    Mohamed, Dalia Mohamed Fawzy
    Hassan, Nihal Adel
    Osman, Amr Abdellatif
    Osman, Moataz Hamed
    [J]. CLINICAL OPHTHALMOLOGY, 2019, 13 : 921 - 925
  • [8] Intravitreal steroid decreases macular thickness fluctuations in patients with diabetic macular edema
    Roan, Vivian
    Kuo, Blanche
    Liu, Brian
    Valentim, Carolina Carvalho Soares
    Singh, Rishi P.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [9] Investigation of Choroidal Thickness Changes after Intravitreal Bevacizumab Treatment in the Treatment of Diabetic Macular Edema
    Isik, M. U.
    Guven, Y. Z.
    Ozturk, A. E.
    Cagiltay, E.
    [J]. EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2020, 30 (1_SUPPL) : 31 - 32
  • [10] Comparison of Subfoveal Choroidal Thickness in Diabetic Patients with/without Macular Edema
    Celik, Erkan
    Cakir, Burcin
    Dogan, Emine
    Turkoglu, Elif Betul
    Alagoz, Gursoy
    [J]. OPHTHALMOLOGICA, 2014, 232 : 21 - 21